Episoder
-
Mangler du episoder?
-
What are the practical considerations when determining the duration of antiplatelet regimens following PCI?
In this interview, Mirvat Alasnag, FACP, FACC, FSCAI, FSCCT, and Sun Moon Kim, MD, FSCAI, FACC, discuss Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy.
In this interview, Judith S. Hochman, MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Statin intolerance is one of the most vexing problems encountered by patients and providers. The CLEAR Outcomes trial directly addresses this problem, using a drug, bempedoic acid, that works only in the liver, thereby reducing the potential for side effects.
In this interview, Steven E. Nissen MD, MACC and Laxmi Mehta MD, FACC, discuss Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Obesity is a driver of Type 2 diabetes, hypertension, abnormal lipids and is an independent risk factor for cardiovascular events and death. The recent discovery of medications with robust ability to affect appetite is making successful and maintained weight loss a reality. In individuals with obesity, semaglutide produces 17% weight loss on average and tirzepatide, under review by the FDA, 22% weight loss on average. While cost and expertise in prescribing are still barriers to implementation in practice, these new medications offer promise in fighting the ever rising rates of obesity.
In this interview, Donna Ryan MD and Anthony N. DeMaria MD, MACC discuss When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
In this interview, Michael J. Ackerman MD, PhD, and Christopher M. Kramer MD, FACC, with Jeffrey Hsu MD, PhD, discuss ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Patients receiving chemotherapy regimens containing anthracyclines for lymphoma were significantly less likely to show evidence of heart dysfunction after taking atorvastatin for 12 months, according to research from the STOP-CA trial, a multicenter, randomized, double-blind, placebo-controlled study presented at ACC.23/WCC.
In this interview, Bonnie Ky MD, MSCE and Anthony N. DeMaria MD, MACC discuss “Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial.”
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Clinicians need more tools to reduce the number of unnecessary tests. Clinical likelihood models represent such tools, and this study demonstrated favorable prognosis for patients who were deferred for testing using the risk factor-weighted clinical likelihood model and the coronary artery calcium score-weighted clinical likelihood model.
In this interview, Simon Winther MD, PhD and Laxmi Mehta MD, FACC discuss JACC piece: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
The PRECISE trial examined how to evaluate patients with chest pain most effectively, minimizing unnecessary testing.
In this interview, Pamela S. Douglas MD MACC, FASE, FAHA and Richard A. Chazal MD, MACC discuss PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected CAD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Iron deficiency is very common in patients with heart failure, affecting between one third to a half of all patients. IRONMAN will help determine if treatment with intravenous iron can help patients feel better, and reduce the risk of being hospitalized for heart failure or dying.
In this interview, Professor Paul Kalra MD, FRCP and Roger S. Blumenthal MD, FACC discuss IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a fibrate-like therapy, there was no clinical benefit.
In this interview, Aruna Das Pradhan MD, MPH and Allen J. Taylor MD, FACC discuss PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
The drug treatments we use to manage atrial fibrillation don't change the progression in the disease.
Catheter ablation, even when performed in younger and healthier patients, modifies the disease trajectory and prevents progression.
In this interview, Jason G. Andrade MD, FRCPC and Christopher M. Kramer MD, FACC discuss AHA Late-Breaker: PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference.
In this interview, Michelle L. O'Donoghue MD, MPH and Nanette Kass Wenger MD, MACC discuss AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes remains the biggest cause of chronic kidney disease, over half of patients with chronic kidney disease do not have diabetes, so treatments that work in people with and without diabetes are key.
In this interview, David Preiss MBChB, MRCP, FRCPath, PhD and Cindy L. Grines MD, FACC, MSCAI discuss AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with CKD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
-
A new study examined a very common clinical question of which loop diuretic or water pill is better in patients living with heart failure - torsemide or furosemide? Prior studies suggested that torsemide might be better than furosemide but they had never been compared head-to-head in a large clinical trial.
The TRANSFORM-HF trial compared these 2 therapies against each other.
In this interview, Robert J. Mentz MD and Laxmi Mehta MD, FACC discuss the primary findings of AHA Late-Breaker: TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
- Se mer
